16 reports

  • INHERENT CHALLENGES WITH OLIGONUCLEOTIDE THERAPIES
  • ANTISENSE/RNAI OLIGONUCLEOTIDES - MARKET SIZE AND FORECAST 2017-2022

About Oligonucleotide Therapeutics Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases. Technavio’s analysts forecast...

  • Oligonucleotide
  • Therapy
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.

Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthesis Service Type Segment to Hold ##% Market Share by 2025 ##.

  • Genomics
  • Oligonucleotide
  • World
  • Market Size

Oligonucleotide Synthesis Market ##.

  • Genomics
  • Oligonucleotide
  • APAC
  • World
  • Forecast

Oligonucleotide Synthesis Market by Offering, by Application, by End User, by Geography - Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023 Chapter ##.

  • Genomics
  • Oligonucleotide
  • Europe
  • North America
  • World

Global Oligonucleotide Synthesis Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Product, by Application, by End User Chapter ##.

  • Genomics
  • Oligonucleotide
  • World
  • Forecast

Oligonucleotide Testing Market Size, Forecast And Trend Analysis, 2014 - 2024 Chapter ##.

  • Genomics
  • Oligonucleotide
  • United States
  • Forecast
  • DNA OLIGONUCLEOTIDES
  • OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%. The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech...

  • Oligonucleotide
  • North America
  • United States
  • Forecast
  • Merck & Co., Inc.
  • GLOBAL OLIGONUCLEOTIDE POOL MARKET SHARE, BY APPLICATIONS, 2016 (%)
  • GLOBAL OLIGONUCLEOTIDE POOL MARKET BY REGION, 2016 (%)

The Global Oligonucleotide pool market was valued at $ 1,292.8 million in 2016 and expected to reach at $2,324 million by 2022 at a CAGR of 8.5% during the forecast period. The major factors responsible for the growth of global Oligonucleotide pool market are big pharmaceutical companies investing in oligonucleotide therapeutics for drug...

  • Oligonucleotide
  • United States
  • World
  • Forecast
  • Agilent Technologies, Inc.
  • OLIGONUCLEOTIDES SEGMENT TO COMMAND THE LARGEST SHARE IN THE
  • SYNTHETIC BIOLOGY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2015-2022 (USD MILLION)

The global synthetic biology market is projected to grow at a CAGR of 19.9%. in the next five years The synthetic biology market is expected to reach USD 8.84 billion by 2022 from an estimated USD 3.57 billion in 2017, at a CAGR of 19.9%. The key factors driving the growth of this market include the wide range of applications...

  • Oligonucleotide
  • North America
  • United States
  • Market Size
  • Thermo Fisher Scientific, Inc.
  • ANTISENSE OLIGONUCLEOTIDE TO ACTIVATE DYSTROPHIN FOR DUCHENNE MUSCULAR DYSTROPHY - DRUG PROFILE
  • ANTISENSE OLIGONUCLEOTIDE TO ACTIVATE DYSTROPHIN FOR DUCHENNE MUSCULAR DYSTROPHY - DRUG PROFILE

Dystrophin (DMD) - Pipeline Review, H2 2017 Summary According to the recently published report ’Dystrophin (DMD) - Pipeline Review, H2 2017’; Dystrophin (DMD) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the...

  • Gene Therapy
  • Neurological Disorder
  • Oligonucleotide
  • Therapy
  • Sarepta Therapeutics, Inc.
  • ANTISENSE OLIGONUCLEOTIDE 2 TO INHIBIT HUNTINGTIN PROTEIN FOR HUNTINGTON'S DISEASE - DRUG PROFILE
  • ANTISENSE OLIGONUCLEOTIDE 1 TO INHIBIT HUNTINGTIN PROTEIN FOR HUNTINGTON'S DISEASE - DRUG PROFILE

Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein) targeted pipeline therapeutics. The report provides comprehensive information...

  • Dementia
  • Oligonucleotide
  • Therapy
  • United States
  • Product Initiative
  • OLIGONUCLEOTIDE FOR HIV
  • OLIGONUCLEOTIDE FOR CANCER

CureVac GmbH - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘CureVac GmbH - Product Pipeline Review - 2016’, provides an overview of the CureVac GmbH’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CureVac...

  • Oligonucleotide
  • Vaccine
  • United States
  • Company Operations
  • CureVac GmbH
  • DEAL RATIONALE
  • 05/01/2017: PROQR TO PRESENT DATA ON QRX-411 AT ARVO

Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders.The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat...

  • Oligonucleotide
  • Pharmaceutical
  • Therapy
  • United States
  • ProQR Therapeutics N.V.
  • OLIGONUCLEOTIDE FOR NEUROINFLAMMATION
  • ANTISENSE OLIGONUCLEOTIDE TO ACTIVATE DYSTROPHIN FOR DUCHENE MUSCULAR DYSTROPHY

nLife Therapeutics, S.L. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘nLife Therapeutics, S.L. - Product Pipeline Review - 2015’, provides an overview of the nLife Therapeutics, S.L.’s pharmaceutical research and development focus. This report provides comprehensive information on the current...

  • Oligonucleotide
  • Research And Development
  • Therapy
  • World
  • Company Operations

Antisense oligonucleotide inhibits the expression of NDM-##.

  • Oligonucleotide
  • Therapy
  • United States
  • Company Operations
  • Sarepta Therapeutics, Inc.
  • Biosearch Technologies targets and partners (2012 -YTD2016)

Partner ##: QIAGEN N. V.

  • Genomics
  • Oligonucleotide
  • United States
  • M&A
  • Biosearch Technologies, Inc.